TIMEx

TIMEx deconvolutes the tumor-immune microenvironment (TIME) from bulk transcriptomics data to estimate proportions of infiltrating immune cell types using pan-cancer single-cell RNA sequencing (scRNA-seq) signatures.

Key Features:

• Deconvolution methodology: Employs a novel deconvolution approach to estimate proportions of various immune cell types from bulk transcriptomic data.
• Pan-cancer scRNA-seq signatures: Utilizes integrated pan-cancer single-cell RNA sequencing (scRNA-seq) signatures as reference profiles for deconvolution.
• Bulk transcriptomics input: Operates on bulk transcriptomic profiles to infer underlying cellular composition of tumor samples.
• Immune cell composition estimation: Infers composition of infiltrating immune cells within tumors, including cell types relevant to progression, metastasis, and treatment response.
• Enhanced immune profiling resolution: Improves resolution of immune cell profiling in complex tissue samples compared to bulk-only analyses.

Scientific Applications:

• Tumor-immune microenvironment profiling: Quantifies immune infiltration across tumor samples to support studies of the TIME.
• Study of cancer progression and metastasis: Enables analysis of how immune cell populations relate to tumor progression and metastatic processes.
• Treatment response and immunotherapy research: Provides estimates of immune composition that can inform treatment response analyses and development of targeted immunotherapies and personalized treatment strategies.
• Pan-cancer comparative analyses: Applies across cancer types using pan-cancer scRNA-seq signatures for comparative studies.

Methodology:

Integrates pan-cancer scRNA-seq signatures and compares bulk transcriptomic profiles to those single-cell signatures to deconvolve and infer cellular composition and cell-type proportions.